Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Medicine

FDA Authorizes Intradermal Use of Jynneos to Increase Supply During Monkeypox Outbreak

Brian Park, PharmD

August 11, 2022

Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged <18 years.

Breast Cancer

Enhertu Approved for HER2-Low Metastatic Breast Cancer

Brian Park, PharmD

August 9, 2022

The approval was based on data from a phase 3 trial that included adults with unresectable or metastatic HER2-low breast cancer who had previous lines of chemotherapy.

Prostate Cancer

New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer

Brian Park, PharmD

August 9, 2022

The approval was based on data from the phase 3 ARASENS trial.

Lymphoma

New Tablet Formulation of Calquence Approved for CLL, SLL, MCL

Brian Park, PharmD

August 8, 2022

The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.

General Oncology

FDA Grants Temporary Import of Contrast Media Agent to Address Shortage

Brian Park, PharmD

July 28, 2022

To address the shortage of contrast media, the FDA will make Iomeron temporarily available in the US at the end of August 2022.

General Medicine

Vaccines for Monkeypox Prevention: Jynneos and ACAM2000

Brian Park, PharmD

Diana Ernst, RPh

July 28, 2022

An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.

Bladder Cancer

Sesen Bio Puts Development of Bladder Cancer Drug Vicineum on Pause

Brian Park, PharmD

July 19, 2022

The biologics license application for Vicineum included preliminary findings from the phase 3 VISTA trial.

General Medicine

Higher Antibody Titers Observed With Moderna’s Bivalent Omicron Booster Candidate

Brian Park, PharmD

July 15, 2022

A 50mcg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against omicron subvariants BA.4 and BA.5 in adults.

General Medicine

Novavax COVID-19 Vaccine Gets FDA’s Emergency Use Authorization

Brian Park, PharmD

July 15, 2022

The Novavax COVID-19 vaccine is administered intramuscularly as a 2-dose primary series (0.5mL each), separated by 3 weeks.

General Medicine

FDA Extends Shelf-Life of Two COVID-19 Monoclonal Antibody Therapies

Brian Park, PharmD

July 5, 2022

The extended shelf-life applies to all unopened vials that have been held in accordance with storage conditions detailed in the manufacturer’s labeling.

Next post in General Medicine